We provide you with 20 years of free, institutional-grade data for KNTE stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of KNTE. Explore the full financial landscape of KNTE stock.
| Reported Date | CIK | Ticker | Type |
|---|
Kinnate Biopharma Inc(NASDAQ:KNTE) 
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. It develops KIN-2787, which is a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma...
Website: https://www.kinnate.com/
Founded: 2018
CEO: Nima Farzan
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about KNTE stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.